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Purpose: Mutated p53 is a tumor suppressor gene, hMLH1 is a mismatch repair gene, and hypermethylation of 
hMLH1 follows microsatellite instability (MSI). This research’s aim is to investigate mutated p53, inactivated hMLH1 
and MSI in gastric cancer and their clinicopathologic implications.
Methods: Between 2003 and 2007, 618 patients underwent curative radical gastrectomy for gastric cancer at Seoul 
National University Bundang Hospital in Korea. We reviewed their medical charts and the pathologic reports 
with immunohistochemistry for p53, hMLH1 and polymerase chain reaction for MSI in 509, 499, and 561 cases, 
respectively. These genetic markers were statistically compared with clinicopathologic features and postoperative 
survival.
Results: The expression ratios of mutated p53, inactivated hMLH1, and MSI were 32.8%, 8.4%, and 8.7%, 
respectively. Mutation of p53 occurred more frequently in aged group (over 40), differentiated group (against the 
non-differentiated group), intestinal type, infiltrative type and positive lymph node metastasis group. Inactivated 
hMLH1 occurred more frequently in aged group, differentiated group, intestinal type and expanding growth type 
group. MSI was found more frequently in aged group, intestinal type and expanding growth type group. All three 
genetic markers had no significant associations with the 5-year survival.
Conclusion: We identified significant relationships between mutated p53, inactivated hMLH1, and MSI with some 
clinicopathologic features of gastric cancer. However, there were no apparent relationships between p53, hMLH1, 
and MSI and prognosis. (J Korean Surg Soc 2010;79:94-102)
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INTRODUCTION
  Based on remarkable advances in recent molecular 
biologic analysis, it is known that gastric cancer is caused 
by a multistep accumulation of genetic alterations,(1) and 
various gene alterations exist in each step of carcino-
genesis.(2) It is known that oncogenes, tumor suppressor 
genes, and replication error repair genes participate in that 
process. The most representative tumor suppressor gene is 
p53.(3) Mutations of p53 are found most often in colorectal 
cancer; however, p53 is found in several other kinds of 
cancers and also in stomach cancer with a high 
frequency.(4) p53 repairs damaged DNA when abnormal 
cells enter into the S phase from the G1 phase, stops cell 
mitosis, and leads to apoptosis of cells when repair does 
not occur.(5) Many researchers have reported a role for 
mutated p53 in stomach cancer; however, considerable 
differences have been shown regarding content, and strong 
evidence about the role as a prognostic factor has not been 
reported. Microsatellite refers to single sequence repeats of 
1 or 6 units existing extensively in genes, and this site is 
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Fig. 1. Immunohistochemical detection of overexpression of p53 (×400) (A). A gastric cancer case with complete loss of the protein in the
invasive part (Left field) and preserved hMLH1 expression in adjacent normal tissue (Right field) (×400) (B).
where mismatch of bases occur during DNA replication. 
If there are abnormal mismatch repair genes, the length 
of the microsatellite will be lengthened or shortened. This 
phenomenon is referred to as microsatellite instability 
(MSI), and is also referred to as the mutator phenotype of 
an abnormal mismatch repair gene.(6) Mismatch repair 
genes are associated with hMSH2, hMSH3, and hMLH1.(7) 
Indeed, there is research that MSI is caused by inactivation 
of the hMLH1 gene induced by hypermethylation.(8,9) In 
the current study, we investigated the mutated p53, 
inactivated hMLH1 and MSI in gastric cancer and their 
clinicopathologic implications. And then we studied, 
whether these tree genetic markers affect the 5-year survival 
of gastric cancer patients.
METHODS
1) Patients and tissue samples
  618 patients who underwent radical gastrectomy for 
gastric cancer at the Seoul National University Bundang 
Hospital between May 2003 and December 2005 were 
included in this study. We reviewed all the patients charts 
for their characteristics, clinicopathologic items and 
follow-up data. The median follow-up period was 36 
months (1∼60). Before surgery, informed consent was 
obtained from all participating patients. Mutated p53 
protein and inactivated hMLH1 were evaluated by 
immunochemistry in 509 and 499 specimens, respectively 
(Fig. 1). And polymerase chain reaction (PCR) was done 
for MSI in 561 specimens. The pathologic analysis and 
reports after surgery was followed according to the UICC 
6th.
2) Tissue array methods
  Core tissue biopsies (2 mm in diameter) were obtained 
from individual paraffin-embedded gastric tumors (donor 
blocks) and arranged in a new recipient paraffin block 
(tissue array block) using a trephine apparatus (Super-
biochips Laboratories, Seoul, Korea). An adequate case was 
defined as a tumor occupying ＞10% of the core area. As 
an internal control, each block contained normal gastric 
mucosa. Four-μm-thick sections were cut from each tissue 
array block, deparaffinized, and dehydrated.
3) Immunohistochemistry
  Immunohistochemical staining against mutated p53 
protein (1：100, mouse monoclonal antibody DO7; 
DAKO, Carpinteria, CA, USA) and hMLH1 (dilution 1：
50, Clone G168-728, 1μg/ml; Pharmingen, San Diego, 
CA, USA) was performed using a streptavidin-biotin- 
peroxidase complex method after an antigen retrieval 
process using microwaves (3 times for 5 min each) for 
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  Male 411 (66.5)
  Female 207 (33.5)
Age
  Median (range)     58 (25∼89)
Tumor size (cm)
  ＜5 416 (67.2)
  5∼10 168 (27.1)
  ≥10 34 (5.5)
  Mean size (range)    4.69 (0.2∼36)
Tumor location
  Lower 326 (52.8)
  Middle 183 (29.6)
  Upper  93 (15.0)
  Entire  16 (2.6)
Histologic differentiation
  Well  98 (15.9)
  Moderate 198 (32.0)
  Poor 217 (35.1)
  Signet ring cell  87 (14.1)
  Mucinous 18 (2.9)
Lauren classification
  Intestinal 288 (46.4)
  Diffuse 277 (44.8)
  Mixed 53 (8.6)
Lymphatic invasion
  (−) 347 (56.1)
  (＋) 271 (43.8)
Perineual invasion
  (−) 432 (69.9)
  (＋) 186 (30.1)
Vascular invasion
  (−) 556 (90.0)
  (＋)  62 (10.0)
T stage
  T1 334 (54.0)
  T2 168 (27.2)
  T3  97 (15.7)
  T4 19 (3.1)
N stage
  N0 356 (57.5)
  N1 151 (24.4)
  N2  55 (8.9)
  N3  56 (9.0)
Stage
  Ia 288 (46.6)
  Ib  98 (15.9)
  II  87 (14.1)
  IIIa 59 (9.5)
  IIIb  8 (2.9)
  IV  68 (11.0)
mutated p53 protein, and using an autoclave for hMLH1. 
When ＞10% of cancer cells showed nuclear staining, we 
considered the case to be over-expression of the p53 gene 
product or loss of hMLH1 expression.
4) Microsatellite analysis
  The DNA of cancerous tissue from 560 of 618 patients 
with consecutive gastric cancers was obtained from for-
malin-fixed, paraffin-embedded surgical blocks. The ex-
tracted DNA was amplified by PCR with fluorescent 
dye-labeled primers on two mononucleotide repeat micro-
satellite markers, BAT-26 and BAT-25 (located within 
intron 5 of the hMSH2 gene and introns of the c-kit 
oncogene, respectively). DNA was detected by a tempera-
ture-controlled DNA Sequencer (PRISM 377; Perkin-Elmer 
Corp., Foster City, CA, USA), and fragment analyses were 
carried out with Genscan software (Perkin-Elmer Corp.). 
MSI status was determined by size variation and the 
occurrence of additional bands in the PCR product from 
tumor DNA.
5) Statistical analysis
  The χ2-test was used to determine the statistical 
relationship between mutated p53, inactivation of hMLH1, 
MSI expression, and clinicopathologic characteristics. 
Survival curves were estimated using the Kaplan-Meier 
method, and the significance of differences between the 
survival curves was determined using the log-rank test. 
Multivariate survival analysis was performed using the Cox 
proportional hazards model. Statistical significance was 
defined as P＜0.05. All statistical analyses were conducted 
using SPSS, version 15.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
1) Clinicopathologic features
  The clinicopathologic features are summarized in Table 
1. There were 411 male patients, and 207 female patients 
among the 618 cases. The majority of tumors were ＜5 cm 
in size (416 cases [67.2%]). The lower-third of the stomach 
was the most common location (326 cases [52.8%]). 
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(−) (%) (＋) (%) Inactivated (%) Activated (%) Stable (%) Instable (%)
p53 (−) 37 (88.1) 298 (65.5) 0.002 293 (64.7) 37 (84.1) 0.002
(＋)  5 (11.9) 157 (34.5) 160 (35.3)  7 (15.9)
hMLH1 Inactivated  37 (11.0)   5 (3.1) 0.002   7 (1.6) 35 (81.4) 0.011
Activated 298 (89.0) 157 (96.9) 439 (98.4)  8 (18.6)
MSI Stable 293 (88.8) 160 (95.8) 0.002  7 (16.7) 439 (98.2) 0.011
Instable  37 (11.2)   7 (4.2) 35 (83.3)   8 (1.8)
*The chi-square test was used to compare all variables; †MSI = microsatellite instability.
According to the WHO classification, the following 
histologic types were represented: well differentiated, 98 
(15.9%); moderate differentiated, 198 (32.0%); poorly 
differentiated, 217 (35.1%); signet ring cell type, 87 
(14.1%); and mucinous differentiated type, 18 (2.9%). 
Based on the Lauren classification, the intestinal type was 
found in 288 cases (46.4%), which was similar to 277 cases 
(44.8%) of the diffuse type. The distribution of tumor 
stages according to the UICC 6th was as follows: Ia, 288 
(46.6%); Ib, 98 (15.9%); II, 87 (14.1%); IIIa, 59 (9.5%); 
IIIb, 18 (2.9%); and IV, 68 (11.0%). When classified by 
depth of invasion, 334 cases were early gastric cancer and 
168 cases were advanced gastric cancer. 486 patients 
underwent a distal gastrectomy and 114 patients underwent 
a total gastrectomy.
2) Correlation between mutated p53, inactivated 
hMLH1 and MSI
  The association between the expression of mutated p53 
protein, inactivated hMLH1, and MSI is shown in Table 
2. As mutated p53 is more highly expressed, the probability 
of inactivation of hMLH1 was decreased significantly 
(P=0.002), and the probability of detecting MSI was very 
small. When hMLH1 gene is inactivated, there is a 
significant high probability (P=0.011) that MSI (instable) is 
found.
3) Clinicopathologic correlations with mutated 
p53, inactivated hMLH1, and MSI
  The correlation between the expression of mutated p53, 
inactivated hMLH1, and MSI, and gender and age is shown 
in Table 3. The incidence of mutated p53 was slightly 
higher in men, but there was no statistical significance. The 
incidence increased significantly as age increased. The 
group with increased mutated p53 was older than the 
group without increased mutated p53 by an average of 2.84 
years. The group which inactivated hMLH1 was also an 
average of 8.08 years older than the group without 
inactivated hMLH1. Comparing to the other group, the 
MSI-defined group was older by an average of 7.78 years.
  The relationship between each genetic marker and 
tumor location is compared. Tumor location was based on 
the center of lesion, and the group of which cancer 
infiltrates entire stomach so cannot find that where the 
cancer was originated was excluded in order to compare 
the tendency of location effectively. The group of 
inactivated hMLH1, it occurred significantly more 
frequently in the lower-third (P=0.016). The group in 
which there was MSI occurred more frequently in the 
lower-third (P=0.001) too.
  Regarding the relationship of each genetic marker with 
stage, lymph node (LN) metastasis, vascular invasion, neural 
invasion, lymphatic invasion, and overall stage is also 
described in Table 3. In the case of mutated p53 
over-expression, the probability of LN metastasis was 
significantly higher than that of wild type p53 (P=0.025). 
However, no significant relationship was found between 
the other genetic markers and LN metastasis.
  There were some clinical differences according to each 
genetic marker with respect to the WHO classification, 
Lauren's classification, and Ming' s criteria, as shown in 
Table 3. In the case of the WHO classification, for 
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Negative Positive Inactivated Activated Stable Instable
Sex 0.278 0.465 0.538
  Male 225 (65.8) 115 (68.7) 29 (69.0) 306 (66.9) 342 (66.7) 33 (67.3)
  Female 117 (34.2)  52 (31.3) 13 (31.0) 151 (33.1) 170 (33.3) 16 (32.6)
Age 0.022 0.001 ＜0.001
  ≤60 160 (46.8)  60 (35.9)  8 (19.0) 207 (45.3) 231 (45.1)  8 (16.3)
  ＞60 (n=351) 182 (53.2) 107 (64.1) 34 (81.0) 250 (54.7) 281 (54.9) 41 (83.7)
Tumor location‡ 0.960 0.016 0.001
  Upper  55 (16.5)  25 (15.5)  2 (4.8)  73 (16.5)  83 (16.7)  2 (4.1)
  Middle 103 (30.9)  50 (31.1)  9 (21.4) 141 (31.8) 162 (32.6)  9 (18.4)
  Lower 175 (52.6)  86 (53.4) 31 (73.8) 229 (51.7) 252 (50.7) 38 (77.6)
T stage 0.203 0.672 0.547
  T1 187 (54.7)  81 (48.5) 19 (45.2) 249 (54.5) 284 (55.5) 26 (53.1)
  T2  90 (26.3)  57 (34.1) 15 (35.7) 126 (27.6) 133 (26.0) 16 (32.7)
  T3  55 (16.1)  27 (16.2)  7 (16.7)  71 (15.5)  82 (16.0)  7 (14.3)
  T4  10 (2.9)   2 (1.2)  1 (2.4)  11 (2.4)  13 (2.5)  0 (0.0)
LN metastasis 0.025 0.404 0.237
  (−) 201 (58.8)  82 (49.1) 25 (59.5) 257 (56.2) 291 (56.8) 31 (63.3)
  (＋) 141 (41.2)  85 (50.9) 17 (40.5) 200 (43.8) 221 (43.2) 18 (36.7)
Lymphatic invasion 0.421 0.074 0.104
  (−) 187 (54.7)  89 (53.3) 18 (42.9) 255 (55.8) 294 (57.4) 23 (46.9)
  (＋) 155 (45.3)  78 (46.7) 24 (57.1) 202 (44.2) 218 (42.6) 26 (53.1)
Vascular invasion 0.317 0.603 0.281
  (−) 305 (89.2) 152 (91.0) 38 (90.5) 412 (90.2) 461 (90.0) 46 (93.9)
  (＋)  37 (10.8)  15 (9.0)  4 (9.5)  45 (9.8)  51 (10.0)  3 (6.1)
Perineural invasion 0.295 0.419 0.367
  (−) 232 (67.8) 118 (70.7) 28 (66.7) 317 (69.4) 358 (69.9) 36 (73.5)
  (＋) 110 (32.2)  49 (29.3) 14 (33.3) 140 (30.6) 154 (30.1) 13 (26.5)
Overall stage 0.539 0.351 0.309
  Ia 162 (47.4)  65 (38.9) 17 (40.5) 211 (46.2) 242 (47.3) 23 (46.9)
  Ib  52 (15.2)  32 (19.2)  7 (16.7)  74 (16.2)  80 (15.6)  7 (14.3)
  II  51 (14.9)  25 (15.0) 11 (26.2)  62 (13.6)  70 (13.7) 12 (24.5)
  IIIa  31 (9.1)  20 (12.0)  3 (7.1)  45 (9.8)  49 (9.6)  4 (8.2)
  IIIb   8 (2.3)   5 (3.0)  1 (2.4)  10 (2.2)  13 (2.5)  1 (2.0)
  IV  38 (11.1)  20 (12.0)  3 (7.1)  55 (12.0)  58 (11.3)  2 (4.1)
WHO criteria ＜0.001 0.012 0.032
  Differentiated 131 (38.3) 103 (61.7) 27 (64.3) 205 (44.9) 237 (46.3) 30 (61.2)
  Non-differentiated 211 (61.7)  64 (38.3) 15 (35.7) 252 (55.1) 275 (53.7) 19 (38.8)
Lauren’s type ＜0.001 0.004 0.010
  Intestinal 131 (41.2) 104 (69.8) 27 (73.0) 206 (48.8) 238 (50.2) 30 (69.8)
  Diffuse 187 (58.8)  45 (30.2) 10 (27.0) 216 (51.2) 236 (49.8) 13 (30.2)
Ming’s criteria 0.014 0.011 ＜0.001
  Expanding 108 (31.6)  70 (41.9) 22 (52.4) 152 (33.3) 183 (35.7) 31 (63.3)
  Infiltrated 234 (68.4)  97 (58.1) 20 (47.6) 305 (66.7) 329 (64.3) 18 (36.7)
*The chi-square test was used to compare all variables except mean age, which were compared using the unpaired t test; †MSI = microsatellite
instability; ‡‘Entire’ was excluded in order to compare the tendency of location effectively. Bold = statistically significant P-values are indicated.
convenient comparison, well differentiation and moderate 
differentiation were combined in the differentiated group, 
and signet ring cell and poorly differentiated type were 
combined in the undifferentiated group. We then 
examined whether there was a difference in the extent of 
differentiation according to each genetic marker. In the 
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Table 4. The univariate and multivariate analysis
Variables Univariate (P-value) Multivariate (P-value)
Tumor location 0.681 −
Tumor size 0.110 −
Tumor depth 0.004 0.490
Lymph node metastasis 0.048 0.979
TNM stage 0.000 0.000
WHO criteria 0.895 −
Lauren’s classification 0.422 −
Ming’s criteria 0.073 −
Lymphatic invasion 0.000 0.007
Vascular invasion 0.087
Perineural invasion 0.001 0.004
Mutated p53 0.299 −
Inactivated hMLH1 0.436 −
MSI* 0.378 −
*MSI = microsatellite instability.
Fig. 2. Cumulative 5-year survival rates in 509 patients with gastric
cancer according to the p53 expression. There is no 
statistically significant difference of overall cumulative 5-year
survival rates between p53(＋) group and p53(−) group 
(P=0.807).
Fig. 4. Cumulative 5-year survival rates in 561 patients with gastric
cancer according to the MSI expression. There is no 
statistically significant difference of overall cumulative 5-year
survival rates between microsatellite instable group and 
microsatellite stable group (P=0.833). MSS = microsatellite
stable, MSI = microsatellite instable.
Fig. 3. Cumulative 5-year survival rates in 499 patients with gastric
cancer according to the hMLH1 activation. There is no 
statistically significant difference of overall cumulative 5-year
survival rates between inactivated hMLH1 group and 
activated hMLH1 group (P=0.988).
case of mutated p53, it was more significantly expressed in 
the group in which differentiation was better (P＜0.001).
  The mutated p53 was more expressed in the group of 
intestinal type in according to Lauren’s classification 
(P=0.001). According to Ming's criteria, there was slightly 
more expression of mutated p53 in the group of expanding 
growth type (P=0.014). Differentiation was better in the 
group of inactivated hMLH1 (P=0.012) than the group 
without inactivated hMLH1. The inactivation of hMLH1 
and MSI were more commonly detected in the intestinal 
type (P=0.004, P=0.010), and expanding growth pattern 
(P=0.011, P＜0.001).
4) Survival analysis
  Statistically significant variables were depth of tumor, LN 
metastasis, TNM stage, lymphatic invasion, and perineural 
invasion variables examined by univariate survival analysis. 
The over-expressed mutated p53, inactivation of hMLH1, 
and MSI was not related with survival significantly (Fig. 2∼
4). On multivariate analysis, TNM stage, lymphatic 
invasion and perineural invasion were remained 
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significantly associated with survival (Table 4).
DISCUSSION
  With the recent advanced in molecular biology, many 
efforts to investigate the etiology of gastric cancer at the 
DNA level has been accomplished so that various 
oncogenes, inactivation of tumor suppressor genes, and 
growth factor deformation have been reported.(1) The 
unstable oncogenes are considered that playing a important 
role in malignant transformation of normal cells.(10) It is 
believed that they compose a signaling cascade required for 
cell mitosis and differentiation and protein engaging in 
gene regulator, and cell mitosis and differentiation of 
normal cell is inhibited by activation, so cancer occurs.(11) 
Expression of over-expressed mutated p53 by using 
immunohistochemistry was observed in 167 patients among 
509 patients who were analyzed, showing about 32.66% of 
expression rate. In gastric cancer patients, the frequency of 
the mutated p53 protein by using immunohistochemistry 
has been reported in 30∼60% from variable re-
ports.(12-14) Regarding mutation of the p53 with respect 
to age and tumor location, some studies suggested that 
there was the tendency that tumor occurred more in the 
upper-third, while mutation was less expressed in the age 
group ＜60 years of age, but there was no difference 
between the intestinal and diffuse types in histologic 
type.(15) The results of this study were the same with above 
research in that expression was increased. However, there 
was no statistical correlation with location, and a statisti-
cally significant expression was more in the intestinal type 
and expanding type. There is a report that expression of 
mutated p53 protein was observed as 22% of the positive 
rate in early gastric cancer and 34% in advanced gastric 
cancer, especially high in well differentiated, but there isn’t 
any linkage with tumor depth, LN metastasis, and vascular 
invasion.(16) In our study, most of results were the same 
as in the pre-mentioned study, but LN metastasis was 
detected more frequently in the group of mutated p53 than 
group of wild type p53. Some studies wrote that the 
survival rate of gastric cancer patients having over- 
expression of mutated p53 protein was very low since the 
danger of distant metastasis and LN metastasis was 
high.(17,18) Provided that p53 is determined collectively 
with the other tumor markers, on the basis of that it was 
seemed to have a relation with differentiation and LN 
metastasis, it will be able to have clinical implication. There 
are a few researchers, who insist that mutated p53 is related 
to a poor prognosis.(13,17) However, in our study, the 
mutated p53 showed no significant influence to the 5-year 
survival. So we cannot conclude the meaning of mutated 
p53 as an independent prognostic factor. Expression of 
MSI in gastric cancer tissue is variously reported (9.5∼
58.3%), and difference between each result is high.(18-20) 
These differences of expression rates according to 
researchers are considered that each researcher had used 
the different kind of markers or different number of 
markers. The frequency of MSI in this study was somewhat 
low (8.75%), which is attributed to using only BAT-26 and 
BAT-25 as a marker. It was also shown that the extent of 
the inactivated hMLH1 gene was a similar value (8.43%); 
MSI was significantly related to hMLH1 (P=0.011) This 
corresponds with the result of a prior study that the MSI 
phenotype of sporadic gastric cancers is mainly due to the 
inactivation of hMLH1 by hypermethylation.(21) However 
mutated p53 showed inverse relationship with MSI. As our 
results, there is a report that showed the significant inverse 
relationship between MSI and p53 gene alterations in 
colon cancer.(22) They explained that there are two 
different molecular pathways to sporadic cancer; the 
microsatellite stable (but chromosomally unstable) pathway, 
probably initiated by APC mutations, and the MSI 
pathway. With respect to gastric cancer, clear agreement 
about the clinical meaning of MSI has not yet been 
compromised. Regarding the rate of expression of MSI 
according to age and tumor location, it was reported to 
be higher in the lower-third of gastric cancer in some 
existing studies,(20,23) and higher in the old age group in 
other studies.(20,24) However, Tamura et al.(25) insisted 
that MSI expression was frequently observed at tumors 
located in the cardia, and it was not related to age, gender, 
and histologic differentiation. In our research, the rate of 
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expression was high in older age and gastric cancer 
occurred in the lower-third of the stomach. There are some 
suppositions that an increase of an imbalance between 
DNA methyltransferase and demethylase activities with age 
may be responsible for hMLH1 hypermethylation.(26) But 
the mechanism has not been explained, clearly. The rate 
of expression was high in intestinal type and expanding 
growth type of gastric cancer so that our research’s results 
were different from that of Tamura et al. Generally, the 
prognosis of tumor having MSI is good,(27,28) and the 
reason for a good prognosis is that T-cell immune reaction 
against mutated protein is increased in tumor having 
mutator phenotype.(28) As to gastric cancer, there are some 
other studies that have also reported a good prognosis of 
gastric cancer having expression of MSI,(23,24) however we 
could not find a statistically significant relationship 
between MSI expression in gastric cancer and prognosis.
 In conclusion, in this research, we couldn’t find any 
possibility for the independent prognostic factors about 
p53, hMLH1 and MSI. But three genetic markers are 
correlated significantly with some clinicopathologic factors 
that can affect prognosis, like tumor differentiation, type 
and especially LN metastasis. This means that these genetic 
markers can affect the tumor aggressiveness. So if further 
studies are followed, detection of these genetic markers can 
be helpful for tailored treatment plan for each patient.
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